It has been reported that SOX4 is frequently amplified and overexpressed in various malignancies [51], strongly supporting the notion that SOX4 is an oncogene, including in breast, bladder, and prostate cancers [24, 52, 53]. Here, SOX4 is linked to prostate carcinoma.